Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker EWTX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Michael Nofi Chief Financial Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 4,442 | $45.43 | $201.8K Sale | Form 4 ↗ |
| Aug 12, 2026 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 913 | $44.33 | $40.5K Sale | Form 4 ↗ |
| Aug 12, 2026 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 8,276 | $43.66 | $361.3K Sale | Form 4 ↗ |
| Aug 12, 2026 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 8,782 | $43.64 | $383.2K Sale | Form 4 ↗ |
| Jul 1, 2026 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 69,648 | $39.41 | $2.7M Sale | Form 4 ↗ |
| Jul 1, 2026 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 130,352 | $39.41 | $5.1M Sale | Form 4 ↗ |
| May 5, 2026 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 50,000 | $38.57 | $1.9M Sale | Form 4 ↗ |
| May 4, 2026 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 5,230 | $31.29 | $163.6K Sale | Form 4 ↗ |
| Apr 1, 2026 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 28,662 | $32.31 | $926.1K Sale | Form 4 ↗ |
| Mar 31, 2026 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 21,338 | $32.12 | $685.4K Sale | Form 4 ↗ |
| Mar 27, 2026 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 6,735 | $30.98 | $208.7K Sale | Form 4 ↗ |
| Mar 27, 2026 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 9,623 | $30.98 | $298.1K Sale | Form 4 ↗ |
| Jan 21, 2026 | Badreddin Edris Director | EWTX Edgewise Therapeutics, Inc. | Sale | 66,477 | $29.44 | $2.0M Sale | Form 4 ↗ |
| Jan 21, 2026 | Badreddin Edris Director | EWTX Edgewise Therapeutics, Inc. | Sale | 10,463 | $29.44 | $308.0K Sale | Form 4 ↗ |
| Jan 21, 2026 | Badreddin Edris Director | EWTX Edgewise Therapeutics, Inc. | Sale | 7,605 | $29.44 | $223.9K Sale | Form 4 ↗ |
| Jan 21, 2026 | Badreddin Edris Director | EWTX Edgewise Therapeutics, Inc. | Sale | 17,236 | $29.44 | $507.4K Sale | Form 4 ↗ |
| Jan 21, 2026 | Badreddin Edris Director | EWTX Edgewise Therapeutics, Inc. | Sale | 13,690 | $29.44 | $403.0K Sale | Form 4 ↗ |
| Nov 12, 2025 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 100,000 | $21.12 | $2.1M Sale | Form 4 ↗ |
| Nov 11, 2025 | Jonathan C. Fox Director | EWTX Edgewise Therapeutics, Inc. | Buy | 10,700 | $18.64 | $199.4K Buy | Form 4 ↗ |
| Aug 26, 2025 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 100,000 | $14.60 | $1.5M Sale | Form 4 ↗ |
| Aug 12, 2025 | John R. Moore General Counsel | EWTX Edgewise Therapeutics, Inc. | Sale | 2,098 | $13.39 | $28.1K Sale | Form 4 ↗ |
| Aug 12, 2025 | Behrad Derakhshan Chief Business Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 2,491 | $13.39 | $33.4K Sale | Form 4 ↗ |
| Aug 12, 2025 | R. Michael Carruthers Chief Financial Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 1,428 | $13.39 | $19.1K Sale | Form 4 ↗ |
| Aug 12, 2025 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 1,907 | $13.39 | $25.5K Sale | Form 4 ↗ |
| Aug 12, 2025 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 7,972 | $13.39 | $106.7K Sale | Form 4 ↗ |
| Aug 12, 2025 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 2,862 | $13.39 | $38.3K Sale | Form 4 ↗ |
| May 2, 2025 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 1,551 | $16.45 | $25.5K Sale | Form 4 ↗ |
| May 2, 2025 | John R. Moore General Counsel | EWTX Edgewise Therapeutics, Inc. | Sale | 1,930 | $16.45 | $31.7K Sale | Form 4 ↗ |
| May 2, 2025 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 4,276 | $16.45 | $70.3K Sale | Form 4 ↗ |
| May 2, 2025 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 5,187 | $16.45 | $85.3K Sale | Form 4 ↗ |
| May 2, 2025 | Behrad Derakhshan Chief Business Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 1,691 | $16.45 | $27.8K Sale | Form 4 ↗ |
| May 2, 2025 | R. Michael Carruthers Chief Financial Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 1,314 | $16.45 | $21.6K Sale | Form 4 ↗ |
| Apr 3, 2025 | Peter A. Thompson Director, 10% owner | EWTX Edgewise Therapeutics, Inc. | Buy | 124,193 | $20.13 | $2.5M Buy | Form 4 ↗ |
| Apr 3, 2025 | Peter A. Thompson Director, 10% owner | EWTX Edgewise Therapeutics, Inc. | Buy | 372,578 | $20.13 | $7.5M Buy | Form 4 ↗ |
| Apr 3, 2025 | OrbiMed Genesis GP LLC Director, 10% owner | EWTX Edgewise Therapeutics, Inc. | Buy | 124,193 | $20.13 | $2.5M Buy | Form 4 ↗ |
| Apr 3, 2025 | OrbiMed Genesis GP LLC Director, 10% owner | EWTX Edgewise Therapeutics, Inc. | Buy | 372,578 | $20.13 | $7.5M Buy | Form 4 ↗ |
| Mar 7, 2025 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 200 | $30.02 | $6,004 Sale | Form 4 ↗ |
| Mar 7, 2025 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 100 | $30.00 | $3,000 Sale | Form 4 ↗ |
| Feb 6, 2025 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 1,200 | $30.13 | $36.2K Sale | Form 4 ↗ |
| Feb 6, 2025 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 900 | $31.13 | $28.0K Sale | Form 4 ↗ |
| Feb 5, 2025 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 8,015 | $30.02 | $240.6K Sale | Form 4 ↗ |
| Feb 5, 2025 | Kevin Koch President and CEO, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 8,636 | $30.03 | $259.3K Sale | Form 4 ↗ |
| Feb 5, 2025 | Behrad Derakhshan Chief Business Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 10,000 | $30.03 | $300.3K Sale | Form 4 ↗ |
| Jan 28, 2025 | Joanne M. Donovan CMO | EWTX Edgewise Therapeutics, Inc. | Sale | 25,000 | $27.63 | $690.8K Sale | Form 4 ↗ |
| Dec 30, 2024 | Alan J. Russell Chief Scientific Officer, Director | EWTX Edgewise Therapeutics, Inc. | Sale | 100,000 | $27.37 | $2.7M Sale | Form 4 ↗ |
| Dec 24, 2024 | Marc Semigran Chief Development Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 1,729 | $30.08 | $52.0K Sale | Form 4 ↗ |
| Dec 24, 2024 | Marc Semigran Chief Development Officer | EWTX Edgewise Therapeutics, Inc. | Sale | 27,980 | $29.66 | $829.9K Sale | Form 4 ↗ |
47 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances